Belgian healthtech startup Monsana has raised €500,000 in
pre-seed funding from Seeder Fund, LRM, and private investors to accelerate
patient access to innovative clinical trials.
Recruiting patients remains a major bottleneck in the
development of new medicines. About 70 per cent of trials are delayed by
enrolment challenges, and too often, eligible patients aren’t identified in time
to access promising treatments.
Monsana addresses this challenge with an AI-powered platform
that reads and interprets unstructured medical data, matching patients to the
right studies quickly, accurately, and cost-effectively. The result is tighter
collaboration between physicians and pharmaceutical companies, lower costs, and
fewer eligible patients slipping through the cracks.
Founded in June 2024 by Dr. Valerie Vandeweerd (CEO) and
Simeon Devos (CTO), Monsana is rooted in medical and personal experience. Dr
Vandeweerd, a former gynaecologist and clinical trial expert at Johnson &
Johnson, saw firsthand how difficult it can be to connect patients with
studies, even when her own family urgently requireded experimental treatment.
The platform has already proven effective in Belgian
hospitals, doubling the number of patients identified in a fraction of the
time, and Monsana is working with several Belgian hospitals and international
pharma partners as it prepares to expand to neighboring countries.
With this new investment, Monsana will deepen
collaborations with hospitals, CROs, and pharmaceutical companies, while
advancing a responsible, trust-first approach to medical AI.
Leave a Reply